Epstein-Barr virus infections- Pipeline Insight, 2026

DelveInsight’s, “Epstein-Barr virus infections- Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Epstein-Barr virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Epstein-Barr virus infections: Understanding

Epstein-Barr virus infections: Overview

Epstein–Barr virus (EBV) infection is caused by the Epstein–Barr virus, also known as human herpesvirus 4 (HHV-4), a ubiquitous double-stranded DNA virus belonging to the Herpesviridae family. EBV is one of the most prevalent human viruses, infecting more than 90% of the global adult population. The virus is primarily transmitted through saliva, although transmission can also occur via blood transfusions, organ transplantation, and, less commonly, sexual contact. Following primary infection, EBV establishes lifelong latency in B lymphocytes, with intermittent reactivation that enables viral shedding and transmission.

Primary EBV infection is often asymptomatic during childhood but commonly manifests as infectious mononucleosis in adolescents and young adults. Typical clinical features include fever, sore throat, cervical lymphadenopathy, fatigue, hepatosplenomegaly, and transient elevations in liver enzymes. While most cases are self-limiting and managed with supportive care, immunocompromised individuals are at an increased risk of severe EBV-related complications, including post-transplant lymphoproliferative disorder (PTLD), chronic active EBV infection, and other lymphoid proliferative diseases.

EBV is also recognized for its oncogenic potential and its association with several malignancies and immune-mediated disorders. Persistent latent infection has been linked to nasopharyngeal carcinoma, endemic Burkitt lymphoma, Hodgkin lymphoma, a subset of gastric carcinomas, and certain T-cell and NK-cell lymphomas. In addition, growing evidence suggests a role for EBV in the development of autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus. Ongoing research is focused on advancing antiviral therapies, immunotherapies, adoptive T-cell therapies, and prophylactic and therapeutic vaccine candidates to improve the prevention and management of EBV-associated diseases.

"Epstein-Barr virus infections- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Epstein-Barr virus infections pipeline landscape is provided which includes the disease overview and Epstein-Barr virus infections treatment guidelines. The assessment part of the report embraces, in depth Epstein-Barr virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Epstein-Barr virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Epstein-Barr virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Epstein-Barr virus infections.

Epstein-Barr virus infectionsEmerging Drugs Chapters

This segment of the Epstein-Barr virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Epstein-Barr virus infections: Emerging Drugs

• mRNA-1189: Moderna Therapeutics

mRNA-1189 is an investigational lipid nanoparticle (LNP)-encapsulated mRNA vaccine being developed by Moderna for the prevention of Epstein-Barr virus (EBV) infection and its associated diseases. The vaccine encodes four EBV envelope glycoproteins—gp220, gp42, gH, and gL—which are translated in host cells following intramuscular administration to elicit both neutralizing antibody and cellular immune responses against EBV. mRNA-1189 is primarily being developed to prevent infectious mononucleosis (IM) and may also reduce the risk of long-term EBV-associated complications. Currently, the drug is being evaluated in the Phase I/II trial for the treatment of Epstein-Barr virus infections.

• LB-DTK-MV: LucasBio

LB-DTK-MV is an investigational allogeneic multi-virus-specific T-cell (VST) therapy being developed by LucasBio for the treatment of Epstein-Barr virus (EBV), cytomegalovirus (CMV), and BK virus (BKV) infections, particularly in immunocompromised patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT) or anticancer therapy. The therapy consists of donor-derived virus-specific T cells that recognize and eliminate virus-infected cells, thereby restoring antiviral immunity in patients with refractory or antiviral-resistant infections. Currently, the drug is being evaluated in the Phase I/II trial for the treatment of Epstein-Barr virus infections.

Further product details are provided in the report……..

Epstein-Barr virus infections: Therapeutic Assessment

This segment of the report provides insights about the different Epstein-Barr virus infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Epstein-Barr virus infections

There are approx. 8+ key companies which are developing the therapies Epstein-Barr virus infections. The companies which have their Epstein-Barr virus infections drug candidates in the most advanced stage, i.e. Phase II include, Moderna Therapeutics LucasBio, and others.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Epstein-Barr virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Epstein-Barr virus infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Epstein-Barr virus infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epstein-Barr virus infections drugs.

Epstein-Barr virus infections Report Insights

• Epstein-Barr virus infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Epstein-Barr virus infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Epstein-Barr virus infections drugs?
• How many Epstein-Barr virus infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Epstein-Barr virus infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Epstein-Barr virus infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Epstein-Barr virus infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• LucasBio
• Moderna Therapeutics
• Hornet Therapeutics

Key Products

• LB-DTK-MV
• mRNA-1189
• HTX 201